Are Fredun Pharma latest results good or bad?

Fredun Pharmaceuticals has reported its financial results for the quarter ending March 2025, highlighting a notable performance in the pharmaceutical and biotechnology sector. The company's net sales reached Rs 167.41 crore, reflecting a year-on-year growth of 41.84%, marking the highest quarterly sales in the last five quarters. This indicates a positive trend in sales performance.
In terms of profitability, Fredun Pharmaceuticals achieved an operating profit (PBDIT) of Rs 17.44 crore, also the highest in the past five quarters. The profit before tax (PBT) stood at Rs 8.04 crore, with a year-on-year increase of 37.67%. Additionally, the profit after tax (PAT) reached Rs 7.07 crore, up by 39.7% year-on-year, and the earnings per share (EPS) was reported at Rs 14.98, the highest in five quarters.

However, the company is facing challenges due to rising interest costs, which increased by 63% quarter-on-quarter to Rs 8.15 crore. This rise has led to a decline in the operating profit to interest ratio, now at its lowest level in five quarters, suggesting potential difficulties in managing interest payments.

Overall, the financial results indicate a strong performance in sales and profitability metrics for Fredun Pharmaceuticals, although the company is encountering challenges related to interest expenses. Additionally, there has been an adjustment in its evaluation based on these results.